MetaCap

Anixa Biosciences (ANIX) vs Cumberland Pharmaceuticals (CPIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cumberland Pharmaceuticals (CPIX) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 193.5% versus a loss of 43.8%. Over five years, CPIX leads with a +161.9% price change compared with -38.7% for ANIX. Cumberland Pharmaceuticals is the larger company by market cap ($87.6 million vs $84.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIX-43.78%CPIX+193.47%
+371%+152%-66%
Nov 21, 20251 yearNov 20, 2026
ANIX-40.92%CPIX+134.54%
+256%+92%-72%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIX versus CPIX key metrics
MetricANIXCPIX
Share price$2.44$5.84
Market cap$84.82M$87.57M
1-day change-6.15%-7.30%
YTD return-21.79%+46.73%
1-year return-43.78%+193.47%
5-year return-38.69%+161.88%
Forward P/E—41.71
EPS (TTM)$-0.32$-0.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$44.52M
Revenue growth (YoY)—+17.57%
Net income (latest FY)$-10.93M$-2.84M
Gross margin—85.02%
Operating margin—-6.27%
Net margin—-6.37%
52-week high$5.46$9.28
52-week low$2.32$2.00
Distance from 52-week high-55.31%-37.07%
Analyst consensusstrong_buy—
Avg. price target upside+296.31%—
Average volume282.29K114.52K
Shares outstanding34.76M15.00M
Employees488
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CPIX has outperformed ANIX by 237.2 percentage points over the past year.

About Anixa Biosciences

ANIX stock →

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Cumberland Pharmaceuticals

CPIX stock →

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

ANIX vs CPIX FAQ

Which is bigger, Anixa Biosciences or Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $87.57M compared with $84.82M for Anixa Biosciences (ANIX).

Which stock has performed better over the past year, ANIX or CPIX?

CPIX returned +193.47% over the past 12 months, compared with -43.78% for ANIX (price return, excluding dividends). Past performance does not predict future results.

Are Anixa Biosciences and Cumberland Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons